What is a Wilms tumor (nephroblastoma)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is a Wilms Tumor?

Wilms tumor (nephroblastoma) is the most common primary malignant renal tumor of childhood, accounting for approximately 90% of all childhood renal malignancies and 5-6% of all pediatric cancers. 1, 2

Pathophysiology and Origin

  • Wilms tumor is an embryonal malignancy that develops from remnants of immature kidney tissue that persist after normal renal development is complete 2, 3

  • The tumor histologically mimics renal embryogenesis and is composed of a variable mixture of three elements: stromal, blastemal, and epithelial components 3

  • Nephrogenic rests are considered precursor lesions and represent foci of embryonic metanephric tissue that abnormally persist after completion of kidney development 3

Clinical Presentation

  • The most common presentation is an abdominal mass or swelling, often discovered incidentally without other accompanying signs or symptoms 1

  • The nonspecific nature of symptoms can delay timely diagnosis and treatment 1

  • Approximately 500 new cases are diagnosed annually in the United States 2

Genetic Basis and Predisposition

  • Less than 50% of children with bilateral Wilms tumors have identified predisposition syndromes, though bilateral disease occurs earlier in life than unilateral disease 4

  • The most common single predisposition syndrome is Beckwith-Wiedemann syndrome (BWS) 4

  • Disorders involving WT1 pathogenic variants are more common in children with bilateral Wilms tumors 4

  • Emerging genetic predispositions include variants in REST, TRIM28, DIS3L2, and CTR9 genes 4

  • Children with bilateral disease have a "field defect" in their kidneys with clonal nephrogenesis and increased DNA methylation at the H19 locus on chromosome 11p15.5, putting them at higher risk for subsequent tumors even after treatment 4

Prognosis

  • Current long-term survival rates approach 85% overall, with many low-stage tumors achieving significantly higher survival rates 5

  • This represents dramatic improvement from only 30% survival in the early 20th century 5

  • Most patients now achieve survival rates exceeding 90% through multimodal therapy including surgery, chemotherapy, and radiation given according to risk stratification 2

Surveillance Considerations

  • For patients with genetic predisposition syndromes (WT1, Beckwith-Wiedemann, or DICER1), renal ultrasound surveillance is recommended, though specific frequency varies by syndrome 6

  • Children treated for bilateral Wilms tumor require ongoing surveillance with abdominal ultrasounds every 3 months until at least 8 years of age, regardless of whether they have syndromic features or harbor variants in known predisposition genes 4

  • Females with bilateral disease face higher risk for subsequent Wilms tumors compared to males 4

References

Research

Wilms tumor and associated predisposing syndromes and conditions.

JAAPA : official journal of the American Academy of Physician Assistants, 2025

Research

Wilms Tumor.

The Urologic clinics of North America, 2023

Research

Wilms tumor: an update.

Advances in anatomic pathology, 2014

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Diagnosis and Management of Wilms Tumor

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.